Semaglutide Recall: Northwest Compounders Lot 01-27-2026@14S.5
Announced 2026-04-22 · FDA
The FDA recall concerns 91 vials of Semaglutide-Glycine-Cyanocobalamin Injectable, Rx only, from Northwest Compounders in Beaverton, OR, due to lack of assurance of sterility. The recall is associated with Lot Number 01-27-2026@14S.5 and is limited to Oregon; no corrective action is provided in the notice.
| Brand | PAYLESS COMPOUNDERS, LLC |
|---|---|
| Product | Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR |
| Reason | Lack of Assurance of Sterility |
| Severity | moderate |
| Units affected | 91 |
| Distribution | OR |
| Agency | FDA |
| Recall / campaign no. | Lot Number 01-27-2026@14S.5 |
WHAT YOU SHOULD DO
- Do not use any recalled vials.
- Check your inventory for Lot 01-27-2026@14S.5 and set aside any affected product.
- Contact your pharmacist or Northwest Compounders for disposal or replacement instructions and stop use until advised.
- If you have used this product and have health concerns, contact your healthcare provider immediately.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.